AKT1 and hypoalphalipoproteinemia, primary, 1: Furthermore, in vivo experiments validated the therapeutic efficacy of FHD against NS and the potential mechanisms by targeting PI3K-Akt pathway, PTGS2, MAPK1, and IL-6.